Patient derived organoids to model rare prostate cancer phenotypes

Loredana Puca, Rohan Bareja, Davide Prandi, Reid Shaw, Matteo Benelli, Wouter R. Karthaus, Judy Hess, Michael Sigouros, Adam Donoghue, Myriam Kossai, Dong Gao, Joanna Cyrta

Read Patient derived organoids to model rare prostate cancer phenotypes by Loredana Puca, Rohan Bareja, Davide Prandi, Reid Shaw, Matteo Benelli, Wouter R. Karthaus, Judy Hess, Michael Sigouros, Adam Donoghue, Myriam Kossai, Dong Gao, Joanna Cyrta in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6008438.txt.

Introduction

Puca and co-authors build patient-derived organoids to model rare prostate cancer phenotypes. Their study was published in Nature Communications. Rare tumours lack ready lab models for study. One such form is neuroendocrine prostate cancer. It is uncommon, fierce, and can arise on its own. It can also emerge when standard care stops working. The team grew organoids from needle biopsies of spread lesions. Samples came from four patients in all.

The organoids matched their source tumours closely, they report. Gene, RNA, and gene-control marks all lined up. The models showed how one gene-control factor drives this cancer form. A fast drug screen picked out single drugs and pairs. Some picks hint at new uses for known drugs.

Catalog record

CREATORLoredana Puca, Rohan Bareja, Davide Prandi, Reid Shaw, Matteo Benelli, Wouter R. Karthaus, Judy Hess, Michael Sigouros, Adam Donoghue, Myriam Kossai, Dong Gao, Joanna Cyrta
COLLECTIONPAPERS
FORMATTXT
FILE SIZE54 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6008438

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Patient derived organoids to model rare prostate cancer phenotypes By Loredana Puca, Rohan Bareja, Davide Prandi, Reid Shaw, Matteo Benelli, Wouter R. Karthaus, Judy Hess, Michael Sigouros, Adam Donoghue, Myriam Kossai, Dong Gao, Joanna Cyrta Published in: Nature Communications DOI: 10.1038/s41467-018-04495-z ABSTRACT A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of prostate cancer that may arise de novo or as a mechanism of treatment resistance in patients with pre-existing castration-resistant prostate cancer. There are few available models to study neuroendocrine prostate cancer. Here, we report the generation and characterization of tumor organoids derived from needle biopsies of metastatic lesions from four patients. We demonstrate genomic, transcriptomic, and epigenomic concordance between organoids and their corresponding patient tumors. We utilize these organoids to understand the biologic role of the epigenetic modifier EZH2 in driving molecular programs associated with neuroendocrine prostate cancer progression. High-throughput organoid drug screening nominated single agents and drug combinations suggesting repurposing opportunities. This proof of principle study represents a strategy for the study of rare cancer phenotypes. INTRODUCTION Prostate cancer is the most common cancer in men and second leading cause of male cancer death in the United States1. Nearly all prostate cancer patients are diagnosed with prostate adenocarcinoma, which arises as an androgen-driven disease. Therefore, a highly effective therapeutic approach for patients with advanced disease is androgen deprivation therapy with gonadal suppression with or without the addition of chemotherapy or the potent androgen synthesis inhibitor abiraterone acetate2,3. However despite initial responses, castration resistance ultimately ensues. With recent therapeutic advances including more effective and earlier use of androgen receptor (AR)-targeted therapies, the landscape of castration-resistant prostate cancer (CRPC) is evolving4. While the majority of CRPC tumors remain AR-driven through the acquisition of activating AR mutations, amplification, splice variants, bypass, or other means, up to 10–20% of CRPC tumors lose AR dependence as a means to evade AR-targeted therapy4. One extreme manifestation is transformation from an AR-positive adenocarcinoma to an AR-negative small cell neuroendocrine carcinoma characterized by distinct morphologic features5. While small cell carcinoma of the prostate rarely arises de novo, castration-resistant small cell neuroendocrine prostate cancer evolves clonally from prostate adenocarcinoma during disease progression retaining early prostate cancer genomic alterations and acquiring distinct genomic, epigenetic, and pathway changes6. Patients with either de novo small cell neuroendocrine prostate cancer or castration-resistant neuroendocrine prostate cancer (CRPC-NE) are often treated with platinum-based chemotherapy similar to patients with small cell lung cancer; however, prognosis is poor and there are no known effective therapies beyond platinum. While in vivo models have been described to model small cell neuroendocrine prostate cancer, the only widely available cell line is the NCI-H660 cell line, derived from a patient initially thought to have small cell lung cancer but later reclassified as prostate based on the presence of the prostate cancer-specific TMPRSS2-ERG gene fusion7. To expand on this unmet need, we developed patient-derived organoids from metastatic biopsies from patients with CRPC-NE. We molecularly characterized these new models and illustrate how they may be utilized to manipulate the expression and activity of oncogenes involved in the establishment of the neuroendocrine phenotype. High-throughput drug screening of patient-organoids nominated novel drug targets and combinations for CRPC-NE. RESULTS Development of patient-derived tumor organoid and xenograft models Fresh tumor tissue from 25 patients with metastatic prostate cancer was used for organoid development with an overall patient success rate of 16% (4/25) (Fig. 1a). Both three-dimensional (3D) and two-dimensional monolayer (2D) organoid-derived cell lines were successfully developed from four patients (liver, lymph node, soft tissue, and bone biopsy sites; Fig. 1b) and propagated (median 12 months) (Fig. 1c). During early passages, a cytology smear was performed to confirm the presence of tumor cells in the culture8 (Fig. 1d) and cancer-associated fibroblasts were isolated and propagated separately for further planned studies on the tumor microenvironment (Supplementary Fig.1). The organoids were also engrafted as patient-derived organoid xenografts (PDOXs) using NOD scid gamma (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice and subsequently re-passaged in vitro as organoids from PDOXs (PDOX-ORG) (Supplementary Fig. 2).Fig. 1Development of patient-derived neuroendocrine prostate cancer models. a Pie chart of prostate cancer needle biopsies considered for the generation of organoids. No organoid established (light orange) represents no viable cells or no cellular material was found in culture after enzymatical digestion of the tissue. Established organoids (p < 1, lighter orange or 1 > p > 10 orange) refers to the presence of clusters of viable cells in culture that became senescent after few passages in culture. Passage >10, dark orange, indicates organoids that have been successfully grown in culture, molecularly characterized and used for functional studies and PDOX development. b Table of clinical data and biopsy sites of fully characterized CRPC-NE organoids. c Schematic view of the models generated from needle biopsies. In the scheme a patient biopsy is processed to generate 3D organoids (ORG). 3D organoids are then used to generate 2D cultures (2D) and also engrafted in an NSG mouse to grow patient-derived organoids xenograft (PDOX) and consequent organoids derived from the PDX (PDOX-ORG). d Air Dried Diff-Quick stained smears of organoids from small cell neuroendocrine prostate carcinoma and high grade adenocarcinomas with neuroendocrine features organoids (×40, scale bar 50 μm). Bright field image analysis (×40 magnification for 3D, ×20 magnification for 2D, scale bar 100 μm) of 3D and 2D organoids. e−h Histology images of native tumor biopsy tissue (Patient) compared with corresponding 3D organoid cultures (ORG), patient-derived organoids xenograft tissue PDOX (×20 magnification, scare bar 100 μm patient images, ×40, scale bar 50 μm for models). Samples are stained with hematoxylin-and-eosin (H&E) and immunohistochemistry (IHC) for AR, synaptophysin (SYP), chromogranin A (CHGA), and CD56 The pathology of each of the four patient’s metastatic tumor and their matched organoids and PDOXs was classified as neuroendocrine prostate cancer based on tumor morphology, including both pure small cell carcinoma and high-grade carcinoma with extensive neuroendocrine differentiation, and were characterized by the presence of small- to medium-sized round cells with fine chromatin pattern and nuclear molding9,10. All four organoids and their PDOXs lacked AR protein expression and expressed classical neuroendocrine markers by immunohistochemistry (Fig. 1e−h). Molecular characterization of neuroendocrine models To determine how genomically stable the organoids are, we performed whole-exome sequencing (WES) of organoids in both 2D and 3D culture conditions and at serial timepoints (passages 10 and 35) and compared these results with the patient’s matched metastatic tumor biopsy and PDOX. Tumor purity of all models including organoids, PDOXs, and PDOX-derived organoids estimated by CLONET11 was high (median 98%) (Supplementary Fig. 3). Genome-wide copy number alterations were concordant across models and with time including genes commonly altered in advanced prostate cancer6,12 (Fig. 2a, Supplementary Fig. 4).Fig. 2Molecular characterization of patient-derived neuroendocrine prostate cancer models. a Allele-specific copy number of selected genes in organoids at different passages over time. b Transcriptomic analysis via principle component analysis including 26 PCA, 33 CRPC-Adeno, 13 CRPC-NE patient samples and CRPC-NE organoids (orange), CRPC-NE PDOX (green), NIC-H660 cell line (red) using RNAseq expression (FPKMS) of ~20k genes. c Clustering of study cohort samples using genes involved in CRPC-NE phenotype, based on RNAseq Expression (FPKMS). The cohort of localized prostate adenocarcinoma PCA (pink), CPRC-Adeno

Read the complete text